New therapies on the horizon

American Journal of Managed Care

Volumn 7, Issue 5 SUPPL., 2001, Pages

  Virgil Brown, W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AVASIMIBE; BILE ACID; CHOLESTEROL ACYLTRANSFERASE; CHYLOMICRON; COLESEVELAM; COLESTYRAMINE; EZETIMIBE; GLUCURONIDE; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; RESIN; ROSUVASTATIN; UNCLASSIFIED DRUG;

BILE ACID METABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY RISK; DOSE CALCULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ABSORPTION; PATIENT COMPLIANCE; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; TREATMENT OUTCOME;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTYRAMINE; ESTERIFICATION; FLUOROBENZENES; HUMANS; INTESTINAL ABSORPTION; LIPOPROTEINS, LDL; PYRIMIDINES; SULFONAMIDES; UNITED STATES;

EID: 0342467928     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Olsson AG. A new statin: A new standard. Am J Manag Care 2001;7(suppl 5):S152-S154.
2. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
3. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-1900.
4. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58234 and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-1754.
5. Lipka LJ, LeBeaut AP, Veltri EP, Mellars LE, Bays HL, Moore PB. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by SCH 58235 [EZEtTIMIBE]: Pooled analysis of two phase II studies. JACC 2000;35(suppl A):257A.
6. Kosoglou T, Seiberling M, Statkevich P, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. Presented at: American College of Cardiology meeting; March 18, 2001; Florida. Abstract.
7. Bocan TM, Krause BR, Rosebury WS, et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscl Thromb Vascular Biol 2000;20:70-79.
8. Burnett JR, Wilcox LJ, Telford DE, et al. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J Lipid Rese 1999;40:1317-1327.
9. Post SM, Zoeteweij JP, Bos MH, et al. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat. Hepatology 1999;30:491-500.